Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 81

1.

Chemoradiotherapy with Brachytherapy or Electron Therapy Boost for Locally Advanced Squamous Cell Carcinoma of the Anus-Reducing the Colostomy Rate.

Kent C, Bessell EM, Scholefield JH, Chappell S, Marsh L, Mills J, Sayers I.

J Gastrointest Cancer. 2017 Mar;48(1):1-7. doi: 10.1007/s12029-016-9850-4.

2.

Era-by-era improvement in survival for elderly patients with Hodgkin lymphoma; outcome data from a large population-based cohort.

Bishton MJ, Hubbard R, Witherall R, Jones SG, Richardson F, James EJ, Sovani V, Bessell EM, Haynes AP, McMillan AK, Fox CP.

Ann Oncol. 2015 Nov;26(11):2356-7. doi: 10.1093/annonc/mdv359. Epub 2015 Sep 15. No abstract available.

PMID:
26374286
3.

Risk of premature menopause after treatment for Hodgkin's lymphoma.

Swerdlow AJ, Cooke R, Bates A, Cunningham D, Falk SJ, Gilson D, Hancock BW, Harris SJ, Horwich A, Hoskin PJ, Linch DC, Lister A, Lucraft HH, Radford J, Stevens AM, Syndikus I, Williams MV; England and Wales Hodgkin Lymphoma Follow-up Group.

J Natl Cancer Inst. 2014 Aug 19;106(9). pii: dju207. doi: 10.1093/jnci/dju207. Print 2014 Sep.

PMID:
25139687
4.

Hodgkin disease (1973-2002): long-term survival and cure fractions.

Bouliotis G, Bessell EM.

Leuk Lymphoma. 2015 May;56(5):1278-85. doi: 10.3109/10428194.2014.949259. Epub 2014 Oct 9.

PMID:
25085435
5.

Mandard tumour regression grade, perineural invasion, circumferential resection margin and post-chemoradiation nodal status strongly predict outcome in locally advanced rectal cancer treated with preoperative chemoradiotherapy.

Dhadda AS, Bessell EM, Scholefield J, Dickinson P, Zaitoun AM.

Clin Oncol (R Coll Radiol). 2014 Apr;26(4):197-202. doi: 10.1016/j.clon.2014.01.001. Epub 2014 Jan 30.

PMID:
24485884
6.

Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors.

Cooke R, Jones ME, Cunningham D, Falk SJ, Gilson D, Hancock BW, Harris SJ, Horwich A, Hoskin PJ, Illidge T, Linch DC, Lister TA, Lucraft HH, Radford JA, Stevens AM, Syndikus I, Williams MV; England and Wales Hodgkin Lymphoma Follow-up Group, Swerdlow AJ.

Br J Cancer. 2013 Jun 11;108(11):2399-406. doi: 10.1038/bjc.2013.219. Epub 2013 May 7.

7.

Primary cutaneous B-cell lymphoma in Nottinghamshire U.K.: prognosis of subtypes defined in the WHO-EORTC classification.

Bessell EM, Humber CE, O'Connor S, English JS, Perkins W, Dickinson PD, Patel AN.

Br J Dermatol. 2012 Nov;167(5):1118-23. doi: 10.1111/j.1365-2133.2012.11122.x. Epub 2012 Sep 5.

PMID:
22759204
8.

Long-term survival after treatment for Hodgkin's disease (1973-2002): improved survival with successive 10-year cohorts.

Bessell EM, Bouliotis G, Armstrong S, Baddeley J, Haynes AP, O'Connor S, Nicholls-Elliott H, Bradley M.

Br J Cancer. 2012 Jul 24;107(3):531-6. doi: 10.1038/bjc.2012.228. Epub 2012 Jun 19.

9.

MAGIC in practice: experience of peri-operative ECF/X chemotherapy in gastro-esophageal adenocarcinomas.

Reece-Smith AM, Saha S, Cunnell ML, Hameed K, Bessell EM, Duffy JP, Madhusudan S, Parsons SL.

J Surg Oncol. 2012 Nov;106(6):748-52. doi: 10.1002/jso.23187. Epub 2012 Jun 4.

PMID:
22674046
10.

Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk.

Dunlop MG, Dobbins SE, Farrington SM, Jones AM, Palles C, Whiffin N, Tenesa A, Spain S, Broderick P, Ooi LY, Domingo E, Smillie C, Henrion M, Frampton M, Martin L, Grimes G, Gorman M, Semple C, Ma YP, Barclay E, Prendergast J, Cazier JB, Olver B, Penegar S, Lubbe S, Chander I, Carvajal-Carmona LG, Ballereau S, Lloyd A, Vijayakrishnan J, Zgaga L, Rudan I, Theodoratou E; Colorectal Tumour Gene Identification (CORGI) Consortium, Starr JM, Deary I, Kirac I, Kovacević D, Aaltonen LA, Renkonen-Sinisalo L, Mecklin JP, Matsuda K, Nakamura Y, Okada Y, Gallinger S, Duggan DJ, Conti D, Newcomb P, Hopper J, Jenkins MA, Schumacher F, Casey G, Easton D, Shah M, Pharoah P, Lindblom A, Liu T; Swedish Low-Risk Colorectal Cancer Study Group, Smith CG, West H, Cheadle JP; COIN Collaborative Group, Midgley R, Kerr DJ, Campbell H, Tomlinson IP, Houlston RS.

Nat Genet. 2012 May 27;44(7):770-6. doi: 10.1038/ng.2293.

11.

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

Adams RA, Meade AM, Seymour MT, Wilson RH, Madi A, Fisher D, Kenny SL, Kay E, Hodgkinson E, Pope M, Rogers P, Wasan H, Falk S, Gollins S, Hickish T, Bessell EM, Propper D, Kennedy MJ, Kaplan R, Maughan TS; MRC COIN Trial Investigators.

Lancet Oncol. 2011 Jul;12(7):642-53. doi: 10.1016/S1470-2045(11)70102-4. Epub 2011 Jun 5.

12.

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP; MRC COIN Trial Investigators.

Lancet. 2011 Jun 18;377(9783):2103-14. doi: 10.1016/S0140-6736(11)60613-2. Epub 2011 Jun 5.

13.

Prognostic importance of Mandard tumour regression grade following pre-operative chemo/radiotherapy for locally advanced rectal cancer.

Dhadda AS, Dickinson P, Zaitoun AM, Gandhi N, Bessell EM.

Eur J Cancer. 2011 May;47(8):1138-45. doi: 10.1016/j.ejca.2010.12.006. Epub 2011 Jan 8.

PMID:
21220198
14.

Primary cutaneous marginal zone B cell lymphoma in monozygotic twins.

Dickinson PD, Patel A, Wootton C, Bessell EM, O'Connor S.

BMJ Case Rep. 2011 Mar 3;2011. pii: bcr1120103515. doi: 10.1136/bcr.11.2010.3515.

15.

Increasing age at diagnosis and worsening renal function in patients with primary central nervous system lymphoma.

Bessell EM, Dickinson P, Dickinson S, Salmon J.

J Neurooncol. 2011 Aug;104(1):191-3. doi: 10.1007/s11060-010-0457-5. Epub 2010 Nov 20.

PMID:
21103909
16.

Regression of rectal cancer with radiotherapy with or without concurrent capecitabine--optimising the timing of surgical resection.

Dhadda AS, Zaitoun AM, Bessell EM.

Clin Oncol (R Coll Radiol). 2009 Feb;21(1):23-31. doi: 10.1016/j.clon.2008.10.011. Epub 2008 Nov 21.

PMID:
19027272
17.

The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: a comparative study.

Aloysius MM, Zaitoun AM, Beckingham IJ, Neal KR, Aithal GP, Bessell EM, Lobo DN.

Virchows Arch. 2007 Nov;451(5):943-8. Epub 2007 Sep 6.

PMID:
17805566
18.

Primary central nervous system lymphoma: biological aspects and controversies in management.

Bessell EM, Hoang-Xuan K, Ferreri AJ, Reni M.

Eur J Cancer. 2007 May;43(7):1141-52. Epub 2007 Apr 12. Review.

PMID:
17433666
19.

Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors.

Bessell EM, Graus F, Lopez-Guillermo A, Lewis SA, Villa S, Verger E, Petit J.

Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):501-8.

PMID:
15145169
20.

High-dose melphalan followed by radical radiotherapy for the treatment of massive plasmacytoma of the chest wall.

Das-Gupta EP, Sidra GM, Bessell EM, Lush RJ, Byrne JL, Russell NH.

Bone Marrow Transplant. 2003 Oct;32(8):759-61.

PMID:
14520418

Supplemental Content

Loading ...
Support Center